Join over 3,700 drug discovery and development professionals worldwide at the 25th International Molecular Medicine Tri-Conference!
Since its debut in 1993, the annual Molecular Medicine Tri-Conference has become one of the world's leading international events in the field of drug discovery, development and diagnostics. The Tri-Conference unites an ecosystem of 3,700 innovative thinkers and thought leaders throughout biotech, pharma and academia from around the world.
Spanning five days, the 2018 meeting includes 16 parallel conference tracks, 7 Symposia, and 25 in-depth short courses. New this year are 9 skills-based training programs. Compelling talks, including best practice case studies and joint partner presentations, will feature over 500 of your fellow industry and academic colleagues discussing themes of cancer research, big data, molecular diagnostics, precision medicine, rare diseases, data science, human microbiome, point-of-care diagnostics, infectious diseases, and so much more.
Why attend the Tri-Conference?
Plus, Don’t Miss:
NEW in 2018: Training Seminars!
Cambridge Healthtech Institute is pleased to incorporate the addition of our new skill-based Training Seminars to the Molecular Medicine Tri-Conference.
Our Training Seminars offer real-life case studies, problems encountered and solutions applied, along with extensive coverage of the academic theory and background. Each training seminar offers a mix of formal lecture and interactive discussions and activities to maximize the learning experience. These training seminars are led by experienced instructors who will focus on content applicable to your current research and provide important guidance those new to their fields.
Diagnostics World Early Innovator Award:
This year the 2018 Tri-Conference Student Fellowship Applicants are invited to enter the Second Annual Diagnostics World Early Innovator Award. The Award recognizes innovation and creativity in effectively recognizing and solving a real-world clinical, scientific or organizational problem through the application of a unique solution.
Full time graduate students and PhD Candidates are encouraged to apply for the Molecular Medicine Tri-Conference Student Fellowship.
Exhibitor / Sponsor Information:
CHI offers sponsorships which will maximize your exposure before, during and after each event. We can help you achieve your goals by customizing a package that meets with your objectives and provide you with an integrated marketing program for the entire year. Opportunities include but are not limited to exhibits, presentations, branding, targeted delegate dinners and webinars utilizing our extensive database of over 800,000 Life Sciences professionals.
President and Co-founder, Institute for Systems Biology
Dr. Hood’s outstanding contributions have had a resounding effect on the advancement of science since the 1960s. Throughout his career, he has adhered to the advice of his mentor, Dr. William J. Dreyer: “If you want to practice biology, do it on the leading edge, and if you want to be on the leading edge, invent new tools for deciphering biological information.”
Hood was involved in the development of six instruments critical for contemporary biology - namely, automated DNA sequencers, DNA synthesizers, protein sequencers, peptide synthesizers, the ink jet printer for constructing DNA arrays and large scale synthesis of DNA and the nanostring instrument for the single molecule analysis of RNA (and later DNA). These instruments opened the door to high-throughput biological data and the era of big data in biology and medicine. He helped pioneer the human genome program—making it possible with the automated DNA sequencer. Under Hood’s direction, the Human Genome Center sequenced portions of human chromosomes 14 and 15.
In 1992, Hood created the first cross-disciplinary biology department, Molecular Biotechnology, at the University of Washington. In 2000, he left the UW to co-found Institute for Systems Biology (ISB), the first committed to systems approach to biology and disease. He has pioneered systems medicine in the years since ISB’s founding and has argued for a healthcare that is predictive, preventive, personalized and participatory (P4). Hood has made many seminal discoveries in the fields of immunology, neurobiology, cancer biology and biotechnology and, most recently, has been a leader in the development of systems biology and its applications to cancer and neurodegenerative diseases, as well as pioneering technologies and strategies that bring systems biology to personalized medicine.
Hood is now pioneering new approaches to P4 medicine and most recently, has embarked on creating a P4 pilot project on 108 well individuals, that is transforming healthcare and leading to a new healthcare discipline termed scientific wellness.
In addition to his ground-breaking research, Hood has published 750 papers, received 36 patents, 17 honorary degrees and more than 100 awards and honors. He is one of only 15 individuals elected to all three National Academies—the National Academy of Science, the National Academy of Engineering, and the Institute of Medicine. Hood has founded or co-founded 15 different biotechnology companies including Amgen, Applied Biosystems, Rosetta, Darwin, Integrated Diagnostics, Indi Molecular and Arivale.
Dr. Hood has also had a life-long interest in K-12 science education and ISB has been a leader in this area.